People · Operator
Named in public records as an officer, director or promoter · active 2011–2024 · Biotechnology, Biotech, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Alpine Immune Sciences, Inc. | — | Biotechnology | Series C | $234.9M | $2.3B | 2016 |
| Genesis Biopharma, Inc | — | Biotechnology | Series C | $131.5M | $4.1B | 2013 |
| Angion Biomedica Corp. | — | Biotechnology | Series B | $52.0M | $48.3M | 2023 |
| Transplant Genomics Inc. | — | Biotech | Series A | $20.6M | $288.4M | 2017 |
| Tivorsan Pharmaceuticals, Inc. | — | Pharmaceuticals | Series A | $13.8M | $27.9M | 2011 |
Jay Venkatesan at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jay Venkatesan on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Miller | 1 | 29 |
| John Moore | 1 | 12 |
| Jonathan Leff | 1 | 11 |
| Robert Ruffolo | 1 | 8 |
| Michael Meyers | 1 | 5 |
| Robert Connelly | 1 | 4 |
| Stanley Rose | 1 | 4 |
| Peter Lewis | 1 | 4 |
| Jay R. Venkatesan | 1 | 3 |
| DANIEL SOLOMON | 1 | 3 |
| Maria Fardis | 1 | 3 |
| Darren Lee | 1 | 3 |
| Joel Braunstein | 1 | 3 |
| Sanford J. Hillsberg | 1 | 3 |
| James Paul Rickey | 1 | 3 |
| Joseph Loscalzo | 1 | 3 |
| Mark J Ahn | 1 | 3 |
| James Connolly | 1 | 3 |
| Gerald J. Lewis | 1 | 2 |
| Michael Handelman | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.